Clinical Trial Update: The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on Q-1802 combined with XELOX in gastrointestinal tumors, currently in Phase 1/Phase 2 for gastroesophageal junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Q-1802
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: QureBio Ltd. | Conditions: Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN